Department of Gynecology and Obstetrics, University of Cologne, Faculty of Medicine and University Hospital Cologne, Germany.
Breast Cancer Center, Municipal Hospital Holweide, Cologne, Germany.
Biomed Res Int. 2020 Oct 22;2020:3432987. doi: 10.1155/2020/3432987. eCollection 2020.
Literature shows platelet-rich plasma (PRP) to improve overall outcomes in orthopedics, dermatology, ophthalmology, gynecology, and plastic surgery. Data on oncological patients is very limited. Only one publication is available on PRP in breast cancer patients. This work evaluated PRP in sentinel node biopsy procedures for breast cancer patients in terms of complication rates and oncological short-term follow-up.
The evaluated PRP was ACP®, i.e., autologous conditioned plasma by Arthrex®. Between 2015 and 2018, 163 patients were offered to receive an ACP®/PRP injection in their lymph node biopsy site. Recruitment resulted in an approximate one-to-one ratio for analysis. Endpoints were major (revision) and minor (seroma, hematoma, and infection) complications rates as well as distant metastases, local recurrence, and overall survival. Median follow-up was 30 months.
Complication rates and oncological follow-up showed PRP to be applicable to use in a sentinel node biopsy scenario in breast cancer patients. There were 0 revisions in the ACP®/PRP group and 1.2% revisions in the control group (not significant). Oncological follow-up showed zero (0) distant metastases and local recurrences as well as a 100% 30-month overall survival.
This is the first analysis of ACP®/PRP used in breast cancer patients in a sentinel node biopsy setting worldwide. PRP does not seem to increase rates of local recurrence within this 30-month follow-up time frame. Also, trend towards decreasing complication rates could be shown.
文献表明，富血小板血浆（PRP）可改善骨科、皮肤科、眼科、妇科和整形手术的整体效果。关于肿瘤患者的数据非常有限。只有一篇关于乳腺癌患者 PRP 的出版物。这项工作评估了 PRP 在乳腺癌患者前哨淋巴结活检中的应用，包括并发症发生率和肿瘤短期随访。
评估的 PRP 是 ACP®，即 Arthrex®的自体条件血浆。2015 年至 2018 年期间，有 163 名患者被提议在前哨淋巴结活检部位接受 ACP®/PRP 注射。招募结果为分析提供了大致一比一的比例。终点是主要（修订）和次要（血清肿、血肿和感染）并发症发生率以及远处转移、局部复发和总生存率。中位随访时间为 30 个月。
并发症发生率和肿瘤随访显示 PRP 可适用于乳腺癌患者的前哨淋巴结活检。在 ACP®/PRP 组中无 0 次修订，在对照组中为 1.2%（无显著差异）。肿瘤随访显示无远处转移和局部复发，以及 100%的 30 个月总生存率。
这是全球首次分析 ACP®/PRP 在乳腺癌患者前哨淋巴结活检中的应用。在这个 30 个月的随访时间内，PRP 似乎不会增加局部复发的发生率。此外，还可以显示出并发症发生率降低的趋势。
